All Posts Tagged With: "CR"
(MITI) Micromet Begins New Trial
Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic...
(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise
Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting...
(CTIC) Cell Therapeutics Posts Positive Pixantrone Data
Cell Therapeutics Inc. (CTIC) recently announced that data from an early stage study of its lead pipeline candidate, pixantrone, for an additional indication, was published in Cancer, an online journal.
The...
(HNAB) Hana Bioscience Encouraging Phase II Results
Written by Grant Zeng, CFA
Hana Biosciences Inc. ( HNAB ) A decent pipeline with late stage candidates…
South San Francisco, CA based Hana Biosciences, Inc....
(CR) Crane First Quarter Earnings Posted Ahead of Expectations
Crane Co. (CR) posted first-quarter 2010 results after the closing bell on Monday. The company recorded a 43% growth in net income to $33.2 million from $23.3 million in the year-ago period. Earnings per share...
(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review
Recently, VIVUS, Inc. (VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food...
(CR) Crane Company Earnings Surprised by 25% in the Third Quarter
Crane Company (CR) recently raised the bottom end of its full-year earnings guidance. The company has surprised on estimates 4 quarters in a row by an average of 24.22%. Crane is trading with a forward P/E...